DexCom continues earnings boost as it prepares to launch new glucose device; up 10%
JHVEPhoto/iStock Editorial via Getty Images


DexCom is up 10% in late Friday morning trading as the continuous glucose monitoring company benefits from quarterly results that beat on the bottom line.
In its Q4 2022 results conference call after the closing bell Thursday, the company said it has already ramped up production for its US launch of its new G7 device, expected on Feb. 17. DexCom (NASDAQ:DXCM) management said that feedback from users outside the U.S. has been very positive. The monitor has a 60% smaller form factor.

For those watching the Super Bowl on Sunday, DexCom (DXCM) is running a commercial about the launch of G7 featuring singer Nick Jonas.
Seeking Alpha's Quant Rating views DexCom (DXCM) as a hold with high marks for growth and profitability.